Personalized Neoantigen Vaccine (Washington University School of Medicine) (Washington University School of Medicine)

A personalized neoantigen vaccine developed by Washington University School of Medicine for the treatment of pediatric patients with recurrent or refractory brain tumors. This therapeutic approach involves identifying unique genetic mutations (neoantigens) within an individual patient's tumor through exome and cDNA sequencing. These identified neoantigens are then incorporated into a custom-made vaccine—either as synthetic long peptides or a polyepitope DNA plasmid—designed to elicit a specific T-cell immune response against the tumor. In clinical trials, the vaccine is typically administered in combination with the adjuvant Poly ICLC (a TLR3 agonist) to enhance immunogenicity. Delivery methods include intramuscular administration, sometimes utilizing specialized devices like the TDS-IM v2.0 for DNA-based formulations.

Other names

Personalized neoantigen peptide vaccinePersonalized neoantigen DNA vaccineNeoepitope-based Personalized VaccinePersonalized Neoantigen Vaccine for Pediatric Brain Tumors